|
1
|
Piazuelo MB and Correa P: Gastric cancer:
Overview. Colomb Med (Cali). 44:192–201. 2013.PubMed/NCBI
|
|
2
|
Correa P: Human gastric carcinogenesis: A
multistep and multifactorial process-First American Cancer Society
Award Lecture on Cancer Epidemiology and Prevention. Cancer Res.
52:6735–6740. 1992.PubMed/NCBI
|
|
3
|
Stock M and Otto F: Gene deregulation in
gastric cancer. Gene. 360:1–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Y, Li M, Zang W, Ma Y, Wang N, Li P,
Wang T and Zhao G: MiR-429 up-regulation induces apoptosis and
suppresses invasion by targeting Bcl-2 and SP-1 in esophageal
carcinoma. Cell Oncol (Dordr). 36:385–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Liu F, Fu Y, Chen X and Zhang D:
MiR-520d-5p functions as a tumor-suppressor gene in cervical cancer
through targeting PTK2. Life Sci. 254:1175582020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu HY and Pan SS: MiR-202-5p suppressed
cell proliferation, migration and invasion in ovarian cancer via
regulating HOXB2. Eur Rev Med Pharmacol Sci. 24:2256–2263.
2020.PubMed/NCBI
|
|
10
|
Chen X, Zhang L, Song Q and Chen Z:
MicroRNA-216b regulates cell proliferation, invasion and cycle
progression via interaction with cyclin T2 in gastric cancer.
Anticancer Drugs. 31:623–631. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cai H, Lin H, Cao W, Sun J, Huang Y and
Fang Y: The downregulation of miR-519a predicts poor prognosis and
contributes to tumor progression in gastric cancer. Int J Clin Exp
Pathol. 12:2496–2505. 2019.PubMed/NCBI
|
|
12
|
Yin S, Yang M, Li X, Zhang K, Tian J, Luo
C, Bai R, Lu Y and Wang M: Peripheral blood circulating
microRNA-4636/-143 for the prognosis of cervical cancer. J Cell
Biochem. 121:596–608. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Zhang CD, Ma MH and Dai DQ:
Three-microRNA signature identified by bioinformatics analysis
predicts prognosis of gastric cancer patients. World J
Gastroenterol. 24:1206–1215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Strong VE: Progress in gastric cancer.
Updates Surg. 70:157–159. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng XJ, Lin JC and Tu SP: Etiology and
prevention of gastric cancer. Gastrointest Tumors. 3:25–36. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. CD0040642010.PubMed/NCBI
|
|
18
|
Pyrhonen S, Kuitunen T, Nyandoto P and
Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and
methotrexate (FEMTX) plus supportive care with supportive care
alone in patients with non-resectable gastric cancer. Br J Cancer.
71:587–591. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
von Felden J and Villanueva A: Role of
molecular biomarkers in liver transplantation for hepatocellular
carcinoma. Liver Transpl. 26:823–831. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan QZ, Liu Q, Zhou YQ, Zhao JJ, Wang QJ,
Li YQ, Tang Y, Gu JM, He J, Chen SP, et al: CIK cell cytotoxicity
is a predictive biomarker for CIK cell immunotherapy in
postoperative patients with hepatocellular carcinoma. Cancer
Immunol Immunother. 69:825–834. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Backes C, Meese E and Keller A: Specific
miRNA disease biomarkers in blood, serum and plasma: Challenges and
prospects. Mol Diagn Ther. 20:509–518. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Q, Yang W, Luo Y, Hu S and Zhu L:
Correlation between miR-21 and miR-145 and the incidence and
prognosis of colorectal cancer. J Buon. 23:29–35. 2018.PubMed/NCBI
|
|
23
|
Cai H, Lin H, Cao W, Sun J, Huang Y and
Fang Y: Downregulation of miR-519a predicts poor prognosis and
contributes to tumor progression in gastric cancer. Oncol Res
Treat. 43:19–26. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J and Zou X: MiR-652 serves as a
prognostic biomarker in gastric cancer and promotes tumor
proliferation, migration, and invasion via targeting RORA. Cancer
Biomark. 26:323–331. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu ML, Xiong SW, Zhu SX, Xue XX and Zhou
XD: MicroRNAs in gastric cancer: From bench to bedside. Neoplasma.
66:176–186. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin W, Han H and Liu D: Downregulation
miR-539 is associated with poor prognosis of gastric cancer
patients and aggressive progression of gastric cancer cells. Cancer
Biomark. 26:183–191. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, Zhou HC, Zhang Y and Huang H:
MicroRNA-625-3p inhibits gastric cancer metastasis through
modulating EZH2. Eur Rev Med Pharmacol Sci. 24:1177–1185.
2020.PubMed/NCBI
|
